Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06745804
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:13.541838+00:00
Published At
2026-03-13T00:00:00+00:00
Record Updated At
2026-03-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Locoregionally Recurrent Hormone-receptor Positive Breast Cancer", "Metastatic Hormone Receptor Positive Breast Cancer", "Hormone Receptor Positive Breast Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-13"
protocolSection.identificationModule.nctId
"NCT06745804"
protocolSection.identificationModule.officialTitle
"Phase 1 Imaging Study of 68Ga-R10602-101 in Hormone Receptor-Positive Breast Cancer"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Locoregionally Recurrent Hormone-receptor Positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Hormone Receptor Positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Hormone Receptor Positive Breast Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.